Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Issue 10 (3rd October 2019)

• Record Type: Journal Article
• Authors: Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 15:Issue 10(2019)
• Page Start: 2269
• Page End: 2285
• Publication Date: 2019-10-03
• Subjects: rVSV -- vesicular stomatitis virus -- vector vaccine -- V920 -- VSV-EBOV -- Ebola virus -- Marburg virus -- Lassa virus -- Nipah virus -- emerging infections; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2019.1649532
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: The devastating Ebola virus (EBOV) outbreak in West Africa in 2013–2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.